NanoViricides, Inc.

NanoViricides, Inc. Has Filed its Annual Report: Coronavirus Drug Program Rapidly Moving Towards Clinical Stage

NanoViricides, Inc.: Broad-Spectrum Direct Antiviral Nanomedicine Should Remain Effective Against COVID-19 Virus Variants, Says NanoViricides, Inc.’s President, Dr. Anil Diwan

NanoViricides Has Filed Quarterly Report for Period Ending September 30, 2020 – Has Sufficient Cash, Coronavirus Drug Development Progress

NanoViricides Nominates a Novel Candidate for Advancing Into Clinical Trials for Treatment of COVID-19

NanoViricides to Participate in Panel Discussion at the B. Riley FBR Virtual Infectious Disease Summit Today, July 21, 2020

NanoViricides Closes On $11.5 Million Underwritten Public Offering of Common Stock

NanoViricides, Inc. Prices $10.0 Million Underwritten Public Offering of Common Stock

NanoViricides Announces Addition to Russell Microcap(R) Index

NanoViricides, Inc.: Strong Effectiveness of NanoViricides Drug Candidates Observed in an Animal Model of Infection by an ACE2-using Human Coronavirus

NanoViricides, Inc.: Coronavirus Drug Development Update from NanoViricides, Inc.